États-Unis - anglais - NLM (National Library of Medicine)

par pharmaceutical - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg in 5 ml - valproic acid oral solution is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid oral solution is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precautions (5.1)   for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless th

États-Unis - anglais - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg - valproic acid capsules are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid capsules are indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precaution (5.1) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless the drug is

États-Unis - anglais - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg - valproic acid capsules are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid capsules are indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precaution (5.1) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless the drug is

États-Unis - anglais - NLM (National Library of Medicine)

eugia us llc - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 5 mg in 100 ml - zoledronic acid injection is indicated for treatment of paget’s disease of bone in men and women. treatment is indicated in patients with paget’s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [see clinical studies (14.5) ] . zoledronic acid is contraindicated in patients with the following conditions: - hypocalcemia [see warnings and precautions (5.2) ] - creatinine clearance less than 35 ml/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see warnings and precautions (5.3) ] . - known hypersensitivity to zoledronic acid or any components of zoledronic acid injection. hypersensitivity reactions including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see adverse reactions (6.2) ] . risk summary available data on the use of zoledronic acid in p

Israël - anglais - Ministry of Health

mbi pharma ltd., israel - chenodeoxycholic acid - hard capsule - chenodeoxycholic acid 250 mg - chenodeoxycholic acid - the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (ctx)) in infants, children and adolescents aged 1 month to 18 years and adults.

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dasco proprietary limited - sulfamic acid - powder - sulfamic acid mineral-sulfur-acid active 750.0 g/kg - dairy cleanser - dairy or milking shed - acid soluble dairy residues | milkstone removal | water scale | milk fat | milk protein | mineral deposits

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dasco proprietary limited - sulphamic acid - soluble powder - sulphamic acid mineral-sulfur-acid active 900.0 g/kg - dairy cleanser - dairy equipment stainless steel | dairy plant stainless steel | milking equipment | building | milking machine - milkstone removal | milk fat | milk protein | mineral deposits

États-Unis - anglais - NLM (National Library of Medicine)

pekana naturheilmittel gmbh - lactic acid, dl- (unii: 3b8d35y7s4) (lactic acid, dl- - unii:3b8d35y7s4), sulfuric acid (unii: o40uqp6wcf) (sulfuric acid - unii:o40uqp6wcf), onion (unii: 492225q21h) (onion - unii:492225q21h), chionanthus virginicus bark (unii: s9y4b22u2e) (chionanthus virginicus bark - unii:s9y4b22u2e), phosphorus (unii: 27ylu75u4w) (phosphorus - unii:27ylu75u4w), zinc sulfate heptahydrate (unii: n57ji2k7wp) (zinc cation - unii:13s1s8sf37), corn silk (unii: 7d3vb244ux) (corn silk - unii:7d3vb244ux), syzygium cumini fruit - lactic acid, dl- 6 [hp_x] in 50 ml - for support of proper blood sugar regulation. application of this homeopathic remedy for the designated usage is exclusively based on homeopathic experience. with severe forms of this disease, a clinically proven therapy is indicated.

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty ltd - dodecylbenzene sulfonic acid; formic acid; sulfuric acid - suspension concentrate - dodecylbenzene sulfonic acid emulsifiers & surfactants active 63.0 g/l; formic acid r1 active 65.0 g/l; sulfuric acid mineral-sulfur-acid active 114.0 g/l - dairy cleanser - milk vat - auto wash - sanitiser

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty ltd - nitric acid; ortho phosphoric acid - aqueous concentrate - nitric acid acid-general active 370.0 g/l; ortho phosphoric acid mineral-phosphorus active 127.0 g/l - dairy cleanser - milk vat | bulk milk vat - bacterial prevention, cleansing or disin | disinfecting